BIO-Europe Spring® 2016: ORYX CEO on research partnerships and cancer vaccine studies

May 10, 2016
Bernard Huber, CEO and founder of ORYX Translational Medicine, and Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, talk about ORYX's early cancer drug development strategy and partnering models. During BIO-Europe Spring 2016, in Stockholm, Sweden, they discuss how ORYX works with academia, the company's history in early-stage cancer research and the next steps for its three leading therapeutic vaccines.
Previous Video
BIO-Europe Spring® 2016: Accord Research on perks of business in the Czech Republic
BIO-Europe Spring® 2016: Accord Research on perks of business in the Czech Republic

After a couple of quiet years working on a large project, Czech Republic-based contract research organizati...

Next Video
BIO-Europe Spring® 2016: Selexis CEO talks licensing, academic partnerships and biosimilars
BIO-Europe Spring® 2016: Selexis CEO talks licensing, academic partnerships and biosimilars

Dr. Igor Fisch, CEO of Selexis SA, a drug discovery and cell-line development services company, speaks to M...